Copyright Reports & Markets. All rights reserved.

Global Still's Disease Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Still's Disease Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Still's Disease Treatment Market Size Growth Rate by Product
      • 1.4.2 Certolizumab Pegol
      • 1.4.3 DNX-514
      • 1.4.4 Etanercept
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Still's Disease Treatment Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Still's Disease Treatment Market Size
      • 2.1.1 Global Still's Disease Treatment Revenue 2014-2025
      • 2.1.2 Global Still's Disease Treatment Sales 2014-2025
    • 2.2 Still's Disease Treatment Growth Rate by Regions
      • 2.2.1 Global Still's Disease Treatment Sales by Regions
      • 2.2.2 Global Still's Disease Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Still's Disease Treatment Sales by Manufacturers
      • 3.1.1 Still's Disease Treatment Sales by Manufacturers
      • 3.1.2 Still's Disease Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Still's Disease Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Still's Disease Treatment Revenue by Manufacturers
      • 3.2.1 Still's Disease Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Still's Disease Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Still's Disease Treatment Price by Manufacturers
    • 3.4 Still's Disease Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Still's Disease Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Still's Disease Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Still's Disease Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Still's Disease Treatment Sales by Product
    • 4.2 Global Still's Disease Treatment Revenue by Product
    • 4.3 Still's Disease Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Still's Disease Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Still's Disease Treatment by Countries
      • 6.1.1 North America Still's Disease Treatment Sales by Countries
      • 6.1.2 North America Still's Disease Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Still's Disease Treatment by Product
    • 6.3 North America Still's Disease Treatment by End User

    7 Europe

    • 7.1 Europe Still's Disease Treatment by Countries
      • 7.1.1 Europe Still's Disease Treatment Sales by Countries
      • 7.1.2 Europe Still's Disease Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Still's Disease Treatment by Product
    • 7.3 Europe Still's Disease Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Still's Disease Treatment by Countries
      • 8.1.1 Asia Pacific Still's Disease Treatment Sales by Countries
      • 8.1.2 Asia Pacific Still's Disease Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Still's Disease Treatment by Product
    • 8.3 Asia Pacific Still's Disease Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Still's Disease Treatment by Countries
      • 9.1.1 Central & South America Still's Disease Treatment Sales by Countries
      • 9.1.2 Central & South America Still's Disease Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Still's Disease Treatment by Product
    • 9.3 Central & South America Still's Disease Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Still's Disease Treatment by Countries
      • 10.1.1 Middle East and Africa Still's Disease Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Still's Disease Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Still's Disease Treatment by Product
    • 10.3 Middle East and Africa Still's Disease Treatment by End User

    11 Company Profiles

    • 11.1 Biocon Limited
      • 11.1.1 Biocon Limited Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Biocon Limited Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Biocon Limited Still's Disease Treatment Products Offered
      • 11.1.5 Biocon Limited Recent Development
    • 11.2 Epirus Biopharmaceuticals, Inc.
      • 11.2.1 Epirus Biopharmaceuticals, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Epirus Biopharmaceuticals, Inc. Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Epirus Biopharmaceuticals, Inc. Still's Disease Treatment Products Offered
      • 11.2.5 Epirus Biopharmaceuticals, Inc. Recent Development
    • 11.3 Genor BioPharma Co., Ltd.
      • 11.3.1 Genor BioPharma Co., Ltd. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Genor BioPharma Co., Ltd. Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Genor BioPharma Co., Ltd. Still's Disease Treatment Products Offered
      • 11.3.5 Genor BioPharma Co., Ltd. Recent Development
    • 11.4 Hetero Drugs Limited
      • 11.4.1 Hetero Drugs Limited Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Hetero Drugs Limited Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Hetero Drugs Limited Still's Disease Treatment Products Offered
      • 11.4.5 Hetero Drugs Limited Recent Development
    • 11.5 Mabion SA
      • 11.5.1 Mabion SA Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Mabion SA Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Mabion SA Still's Disease Treatment Products Offered
      • 11.5.5 Mabion SA Recent Development
    • 11.6 Mycenax Biotech Inc.
      • 11.6.1 Mycenax Biotech Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Mycenax Biotech Inc. Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Mycenax Biotech Inc. Still's Disease Treatment Products Offered
      • 11.6.5 Mycenax Biotech Inc. Recent Development
    • 11.7 Oncobiologics, Inc.
      • 11.7.1 Oncobiologics, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Oncobiologics, Inc. Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Oncobiologics, Inc. Still's Disease Treatment Products Offered
      • 11.7.5 Oncobiologics, Inc. Recent Development
    • 11.8 Oncodesign SA
      • 11.8.1 Oncodesign SA Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Oncodesign SA Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Oncodesign SA Still's Disease Treatment Products Offered
      • 11.8.5 Oncodesign SA Recent Development
    • 11.9 Panacea Biotec Limited
      • 11.9.1 Panacea Biotec Limited Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Panacea Biotec Limited Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Panacea Biotec Limited Still's Disease Treatment Products Offered
      • 11.9.5 Panacea Biotec Limited Recent Development
    • 11.10 Pfizer Inc.
      • 11.10.1 Pfizer Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pfizer Inc. Still's Disease Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pfizer Inc. Still's Disease Treatment Products Offered
      • 11.10.5 Pfizer Inc. Recent Development
    • 11.11 Sandoz International GmbH
    • 11.12 Swedish Orphan Biovitrum AB
    • 11.13 Therapeutic Proteins International, LLC
    • 11.14 UCB S.A.

    12 Future Forecast

    • 12.1 Still's Disease Treatment Market Forecast by Regions
      • 12.1.1 Global Still's Disease Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Still's Disease Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Still's Disease Treatment Market Forecast by Product
      • 12.2.1 Global Still's Disease Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Still's Disease Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Still's Disease Treatment Market Forecast by End User
    • 12.4 North America Still's Disease Treatment Forecast
    • 12.5 Europe Still's Disease Treatment Forecast
    • 12.6 Asia Pacific Still's Disease Treatment Forecast
    • 12.7 Central & South America Still's Disease Treatment Forecast
    • 12.8 Middle East and Africa Still's Disease Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Still's Disease Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Still's Disease Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Still's Disease Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Still's Disease Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Still's Disease Treatment in these regions.
      This research report categorizes the global Still's Disease Treatment market by top players/brands, region, type and end user. This report also studies the global Still's Disease Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Biocon Limited
      Epirus Biopharmaceuticals, Inc.
      Genor BioPharma Co., Ltd.
      Hetero Drugs Limited
      Mabion SA
      Mycenax Biotech Inc.
      Oncobiologics, Inc.
      Oncodesign SA
      Panacea Biotec Limited
      Pfizer Inc.
      Sandoz International GmbH
      Swedish Orphan Biovitrum AB
      Therapeutic Proteins International, LLC
      UCB S.A.

      Market size by Product
      Certolizumab Pegol
      DNX-514
      Etanercept
      Others
      Market size by End User
      Clinic
      Hospital
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Still's Disease Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Still's Disease Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Still's Disease Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Still's Disease Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Still's Disease Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Still's Disease Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now